CoChat

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Objective The aim of this study was to determine the long-term effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM) on the clinical features and liver histopathology. Methods In this retrospective study, the long-term histological impacts of SGLT2i in NAFLD patients with T2DM were investigated. Patients Seven patients with NAFLD and T2DM were treated for the long term with 100 mg/day canagliflozin, an SGLT2i, and liver biopsies were obtained at the 3 points of pretreatment, 24 weeks, and ≥1 year (third liver biopsy) after the start of treatment. Six of seven patients were evaluated with third liver biopsy at the point of three or more years. The primary outcome was liver histopathological changes (defined as a decrease in the NAFLD activity score of one point or more without worsening of the fibrosis stage, compared to pretreatment). Results All 7 patients showed worsening of body mass index and waist circumference at the third liver biopsy compared to 24 weeks. However, the scores of steatosis, lobular inflammation, ballooning, and fibrosis stage improved at the third liver biopsy in 57%, 43%, 14%, and 29% of the patients, respectively, compared to pretreatment. One of the seven patients showed histopathological worsening at the third liver biopsy compared to pretreatment, but the improvement was maintained in the other six patients. Conclusion The long-term treatment of NAFLD complicated by T2DM using an SGLT2i is associated with long-term improvement in liver histopathology despite the worsening of clinical features.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2169/internalmedicine.4398-19

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Changes from baseline (first liver biopsy) to 24 weeks (second liver biopsy) and ≥1 year (third liver biopsy) after the start of treatment with SGLT2 inhibitor in individual histopathological components of NASH. Six of 7 patients were evaluated by a third liver biopsy at ≥3 years. Histopathological improvement was defined as a decrease in the NAFLD activity score of one point or more without worsening of the fibrosis stage.
Figure 1. Changes from baseline (first liver biopsy) to 24 weeks (second liver biopsy) and ≥1 year (third liver biopsy) after the start of treatment with SGLT2 inhibitor in individual histopathological components of NASH. Six of 7 patients were evaluated by a third liver biopsy at ≥3 years. Histopathological improvement was defined as a decrease in the NAFLD activity score of one point or more without worsening of the fibrosis stage.CC BY-NC-ND · PubMed Central
Figure 2. Representative pathological images of a worsening case (Case 3) at the third liver biopsy compared to pretreatment are shown. Histological changes at the three points of pretreatment (first liver biopsy), 24 weeks (second liver biopsy), and 3.5 years (third liver biopsy) after the start of SGLT2 inhibitor. (A) Hematoxylin-eosin staining, 100×. (B) Masson trichrome staining, 100×.
Figure 2. Representative pathological images of a worsening case (Case 3) at the third liver biopsy compared to pretreatment are shown. Histological changes at the three points of pretreatment (first liver biopsy), 24 weeks (second liver biopsy), and 3.5 years (third liver biopsy) after the start of SGLT2 inhibitor. (A) Hematoxylin-eosin staining, 100×. (B) Masson trichrome staining, 100×.CC BY-NC-ND · PubMed Central
Figure 3. Representative pathological images of an improved case (Case 4) at the third liver biopsy compared to pretreatment are shown. Histological changes at the three points of pretreatment (first liver biopsy), 24 weeks (second liver biopsy), and 3.5 years (third liver biopsy) after the start of SGLT2 inhibitor. (A) Hematoxylin and Eosin staining, 100×. (B) Masson trichrome staining, 100×.
Figure 3. Representative pathological images of an improved case (Case 4) at the third liver biopsy compared to pretreatment are shown. Histological changes at the three points of pretreatment (first liver biopsy), 24 weeks (second liver biopsy), and 3.5 years (third liver biopsy) after the start of SGLT2 inhibitor. (A) Hematoxylin and Eosin staining, 100×. (B) Masson trichrome staining, 100×.CC BY-NC-ND · PubMed Central
Figure 4. Serial changes in the median values of clinical parameters during the study. Note the significant worsening at the third liver biopsy (body mass index, second vs. third, p=0.018; waist circumference, second vs. third, p=0.018). Significant worsening of glucose metabolism was noted at the third liver biopsy (fasting plasma glucose, second vs. third, p=0.018; HbA1c, second vs. third, p=0.018).
Figure 4. Serial changes in the median values of clinical parameters during the study. Note the significant worsening at the third liver biopsy (body mass index, second vs. third, p=0.018; waist circumference, second vs. third, p=0.018). Significant worsening of glucose metabolism was noted at the third liver biopsy (fasting plasma glucose, second vs. third, p=0.018; HbA1c, second vs. third, p=0.018).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 49

Metadata

Authors
Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Arase, Y., Ikeda, K., & Kumada, H.
Affiliations
Toranomon Hospital (JP)
Venue
Internal Medicine
Published
2020-08-15
Volume
59
Issue
16
Pages
1931-1937
ISSN
  • 0918-2918 (ISSN-L)
  • 1349-7235
OpenAlex
W3027707577
Cited by
48
References
21
Citations by year
2026: 1 · 2025: 5 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 11
FWCI
5.74
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Internal Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Teikyo University School of Medicine
  • Ministry of Health, Labour and Welfare (19HC1001)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
SGLT2 inhibitors, canagliflozin, non-alcoholic fatty liver disease, type 2 diabetes, liver histopathology, NAFLD activity score, liver fibrosis, steatosis, lobular inflammation, ballooning, long-term treatment outcomes
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Adult, Biopsy, Body Weights and Measures, Diabetes Mellitus, Type 2, Female, Humans, Japan, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. https://app.cochat.ai/papers/10.2169/internalmedicine.4398-19
The paper
Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Arase, Y., Ikeda, K., & Kumada, H. (2020). SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology. Internal Medicine. https://doi.org/10.2169/internalmedicine.4398-19

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.